<DOC>
	<DOCNO>NCT00886977</DOCNO>
	<brief_summary>The efficacy safety evaluate YAM80 administer orally patient Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Efficacy Safety YAM80 Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Patients age 25 65 year ALS patient visit clinic six month Forced Vital Capacity ( FVC ) &gt; 70 % Patients walk Change ALSFRSR score 1 4 12 week initial administration Patients willing give inform consent Tracheotomy invasive ventilation Pregnant possibly pregnant female patient Female patient childbearing potential practice contraception two year administration , male patient practice contraception six month administration Patients clinically significant condition cardiovascular , respiratory , haematological , renal disease . Patients treat investigational drug Patients treat ALS drug within 2 week prior first administration</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>ALS</keyword>
</DOC>